AIHW Board AIHW senior staff Annual report Capability statement Collaboration AIHW corporate plan 2016–17 to 2019–20 Customer care charter FOI - freedom of information Indexed list of files Nous review Organisation chart Presentations Privacy of data Public Interest Disclosure Tenders
By category Ageing, disability & carers Families & children Hospitals Housing & homelessness Indigenous Australians Population groups Risk factors, diseases & death Services, workforce & spending
By subject Adoptions Aged care Ageing Alcohol & other drugs Arthritis & musculoskeletal conditions Asthma Australia's health Australia's welfare Burden of disease Cancer Cardiovascular disease Child health, development & wellbeing Child protection Children's services Chronic diseases
Chronic kidney disease Chronic respiratory conditions COPD Deaths Dementia Dental & oral health Diabetes Disability Expenditure Eye health Food & nutrition Health indicators Health performance Homelessness Hospitals Housing assistance Indigenous Australians Injury Life expectancy
Male health Mental health Mothers & babies Overweight & obesity Palliative care Population health Primary health care Prisoner health Risk factors Rural health Safety & quality of health care Veterans' health Workforce Youth health & wellbeing Youth justice
In other sections Data Publications Contact AIHW
Publications CatalogueOrdering publicationsForthcoming publications Online reports Subscribe to release notices
By subject Adoptions Aged care Ageing Alcohol & other drugs AIHW annual reports Arthritis & musculoskeletal conditions Asthma Australia's health Australia's welfare Burden of disease Cancer Cardiovascular disease Child health, development & wellbeing Child protection Children's services Chronic diseases Chronic kidney disease
Chronic respiratory conditions Corporate publications Data linkage Data standards Deaths Dental & oral health Diabetes Disability Expenditure Eye health Food & nutrition General practice Health indicators Health performance Homelessness Hospitals Housing assistance Indigenous Australians Indigenous housing
Injury Life expectancy Male health Mental health services Mothers & babies Overweight & obesity Palliative care Population health Primary health carePrisoner health Risk factors Rural health Safety & quality of health care Veterans' health Workforce Youth health & wellbeing Youth justice
In other sections Subjects Data Contact AIHW
About AIHW data METeOR—metadata online registry Data by subject AIHW data collections Customised data analysis request Data governance framework Data linking Data standards GovHack Privacy of data Accessing Australian Government health and welfare data
By subjectAboriginal and Torres Strait Islander Health Performance Framework Adoptions Aged care Alcohol and other drugs Alcohol data sources Body weight data sources Cancer Children's headline indicators (CHI) Child protection Data sources for monitoring health conditionsDeaths Diabetes Disability
Expenditure FHBH - Fixing houses for better health General Record of Incidence of Mortality (GRIM) books Height and weight data sources Hospitals Indigenous Australians International collaboration Maternity Information Matrix (MIM) Medical indemnity Mental health Mortality Over Regions and Time (MORT) books National Aged Care Data Clearinghouse
National core maternity indicators (NCMI) National framework for protecting Australia’s children (NFPAC) National indicator catalogue National Youth Information Framework (NYIF) Perinatal data Primary Health Network (PHN) Specialist Homelessness Services (SHS) Tobacco data sources Workforce
In other sections Subjects Publications Contact AIHW
AACR ACFADD AHSAC AIHW Board AIHW Ethics Committee AODTS NMDS WG CKDMAC CMAG CVDMAC HEAC
IGIHM JJ RIG MHISSC NAGATSIHID NCSIMG NDDWG NDIMG NHISSC NIAG NIRAPIMG NMDDNMDS
NMHPSC NOPSAD NPDDC NPHEP NPHIC PCDWG PDWG PHIDG PHIG REDWG Workforce committees
Education worksheets Infographics What's in the pipeline Subscribe to education notices Other educational links
Resources by subject All Latest Ageing Australia's health Australia's welfare Carers
Children & youth Disability Disease Drugs
Health Health prevention Indigenous Australians Injury
In other sections Subjects Data Publications Contact AIHW
Job vacancies How to apply for a position at the AIHW Conditions of employment Benefits of working for the AIHW Temporary employment register Occupational Training Program Contact the People Unit Graduates
AIHW Access magazine Media releases Subscribe to release notices Embargoed access to AIHW material Media contacts
You are here:
The use of lung function testing for the diagnosis and management of chronic airways disease
This demonstration data linkage study investigates the use of lung function testing in the diagnosis and management of chronic airways disease. It uses data from the 45 and Up Study linked to Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) data. The study shows that: - contrary to recommended guidelines, most study participants (82%) initiated on medications for managing their chronic airways disease did not have lung function testing performed within 12 months, either before or after their initial prescription - among respondents who reported having current asthma, lung function testing was only claimed for about one-quarter (26%) in a recent 3-year period and 12% had only 1 lung function test claim during that time.The evidence from this study will inform initiatives to help improve appropriate prescribing and health outcomes for people with chronic airways disease. This project also provides a demonstration of methods that could also potentially be used to fill evidence gaps associated with other chronic diseases such as diabetes, arthritis and cancer.
Respiratory medication use in Australia 2003–2013: treatment of asthma and COPD
This report describes patterns of dispensing of respiratory medications in Australia through detailed analyses of Pharmaceutical Benefits Scheme (PBS) data, as well as other sources, to draw inferences about respiratory medication use among patients with asthma and COPD. It provides a valuable update and new information about the use of medicines for asthma and COPD, thus improving our knowledge and understanding about how these diseases are managed in Australia.
Mortality from asthma and COPD in Australia
Asthma death rates in Australia are high compared with many other countries and chronic obstructive pulmonary disease (COPD) is a leading cause of deaths in Australia and internationally. This report provides current information about mortality due to these conditions in Australia, examining trends over time, seasonal variation, international comparison and variation by age, sex, remoteness, Indigenous status, country of birth and socioeconomic disadvantage.
Coronary heart disease and chronic obstructive pulmonary disease in Indigenous Australians
The pattern of coronary heart disease and chronic obstructive pulmonary disease in Indigenous Australians differs to that in non-Indigenous Australians. This paper shows that Indigenous Australians have higher hospitalisation and death rates for these conditions than non-Indigenous Australians, and are more likely to die from these conditions at younger ages. However there are some encouraging trends seen in the Indigenous population, such as declining death rates from coronary heart disease, improved chronic disease management and declining smoking rates.
Monitoring pulmonary rehabilitation and long-term oxygen therapy for people with chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability in Australia. While pulmonary rehabilitation and long term oxygen therapy are recommended treatments for COPD, there is currently no national information about the supply and use of these therapies. This report outlines a proposed approach to monitoring access to, and utilisation of, these therapies, by capitalising on existing data sources and identifying data development opportunities.
Monitoring asthma in pregnancy: a discussion paper
Asthma in pregnant women may have adverse effects on maternal, fetal and infant outcomes, particularly if expectant mothers experience an exacerbation of asthma while pregnant. Pregnancy, in turn, may have adverse effects on asthma control among expectant mothers. This report outlines a proposed approach to monitoring asthma during pregnancy by capitalising on existing data sources as well as identifying data development opportunities.
Asthma hospitalisations in Australia 2010-11
This report provides an overview of hospitalisation patterns over time and across population groups. Asthma hospitalisation rates decreased between 1998-99 and 2010-11, by 33% for children and 45% for adults. The rate of hospitalisation for asthma among Indigenous Australians was 2.1 times the rate for Other Australians. Asthma hospitalisation rates were also higher for people living in areas with lower socioeconomic status.
Geographic distribution of asthma and chronic obstructive pulmonary disease hospitalisations in Australia: 2007-08 to 2009-10
This report investigates how hospitalisation rates for asthma and chronic obstructive pulmonary disease (COPD) vary across Australia. Maps in the report show higher hospitalisation rates for both asthma and COPD in inland and rural areas of Australia. Socioeconomic status, remoteness and the proportion of the population that identifies as Indigenous all have a significant association with the hospitalisation rates for asthma and COPD by area.
Vaccination uptake among people with chronic respiratory disease
Research has shown that vaccinations against influenza and pneumococcal infection can benefit people with obstructive airways disease, which includes asthma and chronic obstructive pulmonary disease (COPD). This report reviews the limited information available in Australia on how many people with asthma and COPD have the vaccination, and finds that the uptake rate is not as high as would be expected if recommendations were being followed.It presents a range of data improvement options that would enhance our ability to monitor vaccination uptake in this and other at-risk population groups.
Medications prescribed for people with obstructive airways disease: antibiotics and inhaled corticosteroids
Appropriate use of medications is important in maximising health benefits for patients, minimising the negative effects of medications, and controlling health costs. This report focuses on the appropriate use of certain medications for the management of obstructive airways disease, including asthma and chronic obstructive pulmonary disease (COPD).Data in this report suggest that antibiotics are commonly used among patients with asthma and COPD, and that supply patterns for inhaled corticosteroids are often not consistent with treatment guidelines for the management of these conditions.
Allergic rhinitis ('hay fever') in Australia
Hay fever is a term commonly used to refer to allergic rhinitis caused by seasonal exposure to pollen. Allergic rhinitis can cause significant irritation and interference in a sufferer's daily activities, considerably reducing their quality of life. It is one of the most common chronic respiratory conditions in Australia, affecting around 15% of Australians or 3.1 million people. The amount of money paid by community pharmacies to wholesalers for medications commonly used to treat allergic rhinitis doubled between 2001 ($107.8 million) and 2010 ($226.8 million).
Asthma in Australia 2011: with a focus chapter on chronic obstructive pulmonary disease
Asthma is an important health problem in Australia. This report brings together data from a wide range of sources to describe the current status of asthma in Australia. It includes information on the number of people who have asthma and who visit their general practitioner, are hospitalised or die due to asthma. Time trends and profiles of people who receive various treatments for asthma are also presented, along with information on those who have written asthma action plans. In addition, comorbidities and quality of life among people with asthma are also investigated. This report also includes a chapter that focuses on chronic obstructive pulmonary diseases in Australians aged 55 years and over.
Contribution of chronic disease to the gap in mortality between Aboriginal and Torres Strait Islander people and other Australians
Chronic diseases are major contributors to the mortality gap between Aboriginal and Torres Strait Islander and other Australians. About 80% of the mortality gap for people aged 35 to 74 years is due to chronic diseases, measured in terms of potential years of life lost. The major contributors are heart diseases, diabetes, liver diseases, chronic lower respiratory disease, cerebrovascular diseases and cancer.
Time trends and geographical variation in re-admissions for asthma in Australia
Re-admissions for asthma can be considered an indicator of health system performance in relation to the management of patients with asthma. This bulletin examines the overall rate of re-admissions for asthmas in Australian and investigates time trends in re-admissions for asthmas as well as differences according to age, sex, socioeconomic status and remoteness of residence.
Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia
In 2004-05, Australia spent $3.3 billion directly on the management of respiratory conditions. In 2007-08, general practitioners managed respiratory problems more than any other condition and in 2006 conditions of the respiratory system were the third most common underlying causes of death. This report presents the epidemiology of each of the main respiratory conditions and highlights their differences and similarities. The conditions addressed include asthma, chronic obstructive pulmonary disease, allergic rhinitis, chronic sinusitis, influenza, pneumonia, bronchiectasis, cystic fibrosis, pneumoconiosis and sleep apnoea.
Asthma among older people in Australia
Over 92% of the 402 asthma deaths in 2006 were among people aged 45 years and over. Asthma in older Australians is distinct in many ways. The presence of comorbid conditions makes the management of asthma in older people more complex. The disease itself is also more persistent and severe than in the younger ages.
Monitoring the impact of air pollution on asthma in Australia: a methods paper
Air pollution can trigger asthma and, in severe cases, has been associated with hospitalisation and death. How much of a problem is air pollution though? What proportion of asthma exacerbations are due to air pollution each year? How much does this vary with extreme events such as bushfires and dust storms? This paper discusses the challenges associated with this type of monitoring, outlines the work that has so far been done in Australia in this area and presents a method for estimating the contribution of air pollution to asthma hospitalisations. The method has been applied to a particular case study 'Melbourne in 2006' to test its potential usefulness.
Asthma in Australian children: findings from Growing Up in Australia, the Longitudinal Study of Australian Children
Within the first 3 years of life, 16.9% of infants experience asthma or wheeze. Among non-asthmatic children aged 4 to 5 years, 4.1% will develop asthma by the seventh year of life. These and other new insights into the incidence, natural progression and outcomes associated with childhood asthma are presented in this report, based on analysis of Growing up in Australia: the Longitudinal Study of Australian Children.
Burden of disease due to asthma in Australia 2003
In 2003 asthma was the leading cause of burden of disease in Australian children, contributing 17.4% of total DALYs and the eleventh-leading contributor to the overall burden of disease in Australia, accounting for 2.4% of the total number of DALYs. Asthma also contributed a substantial proportion to the Indigenous health gap in the burden of non-communicable conditions. It is predicted that asthma will continue to rank as one of the major causes of disease burden in Australia for the next 2 decades, particularly among females.
Refining national asthma indicators: Delphi survey and correlation analysis
This report is the result of a systematic review undertaken by the Australian Centre for Asthma Monitoring (ACAM) to refine and simplify asthma monitoring in Australia. A Delphi survey and correlation analysis were used to review the currently recommended list of 24 national asthma indicators in order to identify a smaller set of core indicators, which provide the most important and relevant information and which are more effective at signalling change for future asthma monitoring activities.
General practice in Australia, health priorities and policies 1998 to 2008
This report looks extensively at changes in the activities of GPs from 1998 to 2008 in the light of numerous government initiatives and changes in the GP workforce and in the population. It shows that GP activity generally correlates well with health policy initiatives and clinical guidelines, notably with Type 2 diabetes and the control of asthma and high blood cholesterol levels. In some areas, however, there is less evidence of an effect so far. The report also raises some potential concerns about the costs from the continued rapid growth in orders for pathology testing and the overall challenge for the GP workforce in dealing with an ageing population with complex needs. Edited by Britt H and Miller GC.
Asthma in Australia 2008
Asthma is an important health problem in Australia. This report brings together data from a wide range of sources to describe the current status of asthma in Australia. It includes information on the number of people who have asthma and who visit their GP, are hospitalised or die due to asthma. Time trends and profiles of people who receive various treatments for asthma are also presented, along with information on those who have written asthma action plans. In addition, comorbidities and quality of life among people with asthma are investigated. This report also includes a chapter that focuses on asthma among Aboriginal and Torres Strait Islander Australians.
Occupational asthma in Australia
This bulletin includes a discussion of the monitoring and surveillance of the disease and its risk factors.
Statistical methods for monitoring asthma
This statistical procedure manual documents and shares the experience of the Australian Centre for Asthma Monitoring (ACAM) in analysing national asthma-specific population data. Since its formation in 2002, ACAM have undertaken extensive analyses of a wide range of administrative and population health data to monitor asthma in Australia. In this manual, the approaches developed by ACAM for interrogating large population datasets from the point of receipt until delivery of final analyses are documented. It is anticipated that the principles applied in relation to interrogating data for asthma monitoring purposes will also be applicable to other chronic disease areas.
Australian asthma indicators: five-year review of asthma monitoring in Australia
In 2004, the Australian Centre for Asthma Monitoring reviewed the proposal indicators for monitoring asthma in Australia and published a set of recommended indicators. An accompanying data development plan was published in 2005. This report reviews the outcomes of the indicator review, the lessons learnt through experience with various data sources, progress so far with asthma data development and where national asthma monitoring might go in the future.
Page 1 of 2